Nexalin Technology Supports Health Tech Investment Act
HOUSTON, TX, April 21, 2025 — Nexalin Technology, Inc. (Nasdaq: NXL; NXLIW) has announced its support for the Health Tech Investment Act (S. 1399), bipartisan legislation introduced in the United States Senate. The bill aims to expand Medicare reimbursement opportunities for FDA-cleared or approved medical devices that incorporate artificial intelligence (AI) or machine learning.
The proposed legislation, sponsored by Senators Mike Rounds (R-S.D.) and Martin Heinrich (D-N.M.), suggests a transitional reimbursement mechanism under Medicare. This mechanism would bridge the gap between device approval and coverage by assigning New Technology Ambulatory Payment Classification (APC) codes to AI-enabled technologies for up to five years. This period would allow the Centers for Medicare & Medicaid Services (CMS) to collect clinical data and assess long-term reimbursement decisions.
Nexalin’s upcoming Gen-3 HALO Clarity™ device, currently under development for FDA submission, is a next-generation neurostimulation system. It integrates advanced AI capabilities into both treatment delivery and patient monitoring. The device is designed to deliver non-invasive, low-frequency waveforms targeting key brain regions associated with anxiety, depression, insomnia, and related mental health conditions.
“The Health Tech Investment Act reflects a shift in national health policy toward supporting intelligent, patient-centered innovations,” said Mark White, CEO of Nexalin. “Our Gen-3 HALO Clarity™ device exemplifies this approach by combining precision neurostimulation with AI-driven tools that improve care coordination, monitoring, and adherence.”
The Gen-3 HALO Clarity™ device expands upon the clinical foundation laid by Nexalin’s earlier-generation systems. It adds intelligent features allowing clinicians to personalize treatment, analyze real-time outcomes, and ensure protocol compliance — whether in the clinic or remotely.
Nexalin views the Health Tech Investment Act as a legislative milestone that could provide a reimbursement framework suited to the Gen-3 HALO Clarity™ device. The Company remains focused on its regulatory and clinical milestones while supporting swift bipartisan action to bring this legislation into law.
About Nexalin Technology, Inc.
Nexalin designs and develops innovative neurostimulation products to combat the global mental health epidemic. The Company’s non-invasive and undetectable devices utilize bioelectronic medical technology to treat mental health issues. Nexalin’s next-generation devices aim to generate enhanced patient response without adverse side effects.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements relate to future events or Nexalin’s future financial performance. The Company’s actual results could differ materially from those indicated by these forward-looking statements. Such statements are subject to numerous conditions beyond the Company’s control, as set forth in the Risk Factors section of the Company’s Report on Form 10-K for the year ended December 31, 2023, and other SEC filings.
